XTX Topco Ltd Takes Position in Mesoblast Limited (NASDAQ:MESO)

XTX Topco Ltd purchased a new position in Mesoblast Limited (NASDAQ:MESO) during the second quarter, Holdings Channel.com reports. The firm purchased 15,063 shares of the company’s stock, valued at approximately $103,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Chase Investment Counsel Corp acquired a new position in Mesoblast in the 1st quarter worth approximately $298,000. Rathbones Group PLC purchased a new stake in shares of Mesoblast in the second quarter valued at $95,000. Pine Valley Investments Ltd Liability Co acquired a new stake in shares of Mesoblast in the second quarter worth $80,000. Perkins Coie Trust Co purchased a new position in shares of Mesoblast during the second quarter valued at $68,000. Finally, Chapin Davis Inc. raised its position in Mesoblast by 50.0% during the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock valued at $102,000 after buying an additional 5,000 shares during the period. Institutional investors and hedge funds own 1.43% of the company’s stock.

Wall Street Analysts Forecast Growth

MESO has been the subject of a number of research reports. StockNews.com lowered Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Maxim Group raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Tuesday, September 24th. Jefferies Financial Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating in a research report on Thursday, August 29th. Cantor Fitzgerald restated an “overweight” rating on shares of Mesoblast in a report on Thursday, August 29th. Finally, Piper Sandler upgraded Mesoblast from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $4.00 to $11.00 in a report on Tuesday, July 23rd. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $11.50.

Mesoblast Price Performance

Shares of MESO opened at $8.27 on Wednesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The firm has a market cap of $944.25 million, a PE ratio of -7.38 and a beta of 3.47. Mesoblast Limited has a twelve month low of $1.61 and a twelve month high of $8.66. The firm’s 50 day moving average price is $6.61 and its 200 day moving average price is $6.53.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.